Journal
ONCOTARGETS AND THERAPY
Volume 10, Issue -, Pages 3187-3192Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S139718
Keywords
lung cancer; ALK; crizotinib; small-cell lung cancer
Categories
Funding
- Zhejiang Province of China [2013KYB051]
- Zhejiang Administration of Traditional Chinese Medicine Foundation [2013ZQ005]
- Science and Technology Planning Project of Zhejiang Province [2015C33194]
- National Clinical Key Specialty Construction Program
Ask authors/readers for more resources
Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is rare. Herein, we report a 49-year-old man diagnosed with adenocarcinoma, who was negative for EGFR and ALK genes as detected by reverse transcription polymerase chain reaction, and was treated with crizotinib. A new biopsy showed a small-cell lung cancer after disease progression. Then, next-generation sequencing (NGS) was carried out and detected a TP53 gene mutation, an ALK rearrangement, and no loss of the retinoblastoma gene (RB). Although a regimen for small-cell lung cancer may be one treatment option, a heterogeneous tumor may exist at the time of diagnosis and manifest during the course of disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available